# US 2010/0166770 A1 · Antagonists of bacterial sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166770 A1
- Document ID: US20100166770A1
- Status: Published application
- Kind: A1
- Application number: 12/486,208
- Filed: 2009-06-17
- Published: 2010-07-01
- Earliest claimed: 2008-06-17
- Assignees: National University of Singapore
- Inventors: VOLKER PATZEL
- Web page: https://patentgrep.com/patent/US20100166770A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 31/04: Antibacterial agents
- C12N 2310/11: Antisense
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA.

## Claims

### Claim 1

An antagonist directed against a bacterial RNA or a precursor thereof, wherein the bacterial RNA has a stem-loop secondary structure.

### Claim 2 (depends on 1)

The antagonist of claim 1, wherein the stem-loop secondary structure is homologous to RNA or DNA host sequences and/or innate bacterial sequences.

### Claim 3 (depends on 1)

The antagonist of claim 1, wherein the bacterial target RNA is from mycobacteria, particularly from M. tuberculosis.

### Claim 4 (depends on 3)

The antagonist of claim 3, which is directed against the bacterial mRNA is from the mycobacterial tuf gene, particularly against a portion thereof comprising the sequence as shown in FIG. 5 (SEQ ID NO: 3).

### Claim 5 (depends on 1)

The antagonist of claim 1 for the prevention and/or treatment of bacterial infections, particularly bacterial infections caused by or associated with intracellular bacteria.

### Claim 6 (depends on 5)

The antagonist of claim 5 for the prevention and/or treatment of mycobacterial infections, particularly bacterial infections caused by and/or associated with M. tuberculosis.

### Claim 7 (depends on 1)

The antagonist of claim 1 which is selected from nucleic acid effector molecules, aptamers, antibodies, and combinations thereof.

### Claim 8 (depends on 1)

The antagonist of claim 1, which is a nucleic acid effector molecule selected from
(i) antisense molecules, ribozymes, siRNA molecules, and shRNA molecules,
(ii) precursors of the molecules from (i) and
(iii) DNA molecules encoding the molecules from (i) and (ii).

### Claim 9 (depends on 1)

The antagonist of claim 1 which is present as:
(i) a naked nucleic acid,
(ii) a non-viral vector including liposomes, cationic lipids, polyethylenimine, poly-L-lysine or other non-viral compounds suitable for gene delivery,
(iii) a viral vector including AAV vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, herpes viral vectors or other viral vectors suitable for gene delivery, or
(iv) a bacterial vector including invasive or intracellular bacterial vectors e.g. based on E. coli, Salmonella species, Listeria monocytogenes, Mycobacteria vectors.

### Claim 10 (depends on 1)

The antagonist of claim 1 which is coupled to nanoparticles, including biodegradable and ferromagnetic nanoparticles.

### Claim 11 (depends on 1)

The antagonist of claim 1 which is covalently or non-covalently linked to a targeting moiety, e.g. a bacterial delivery peptide.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising at least one antagonist of claim 1 together with a pharmaceutically acceptable carrier.

### Claim 13

A method for the prevention and/or treatment of a disorder caused by or associated with a bacterial pathogen, comprising administering to a subject in need thereof a therapeutically effective amount of an antagonist directed against an RNA from said bacterial pathogen or against a precursor of said RNA, wherein said RNA has a stem-loop secondary structure.

### Claim 14 (depends on 13)

The method of claim 13, wherein the stem-loop secondary structure is homologous to RNA or DNA host sequences and/or innate bacterial sequences.

### Claim 15

Use of a bacterial RNA having a stem-loop secondary structure, which resembles a miRNA structure or a miRNA molecule derived from such a structure as a therapeutic or diagnostic agent.

### Claim 16

A screening method for identifying and/or characterizing compounds which act as antagonists against a bacterial RNA or a precursor thereof, wherein the bacterial RNA has a stem-loop secondary structure, which resembles a micro-RNA (miRNA) structure.
